Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06889831 · ClinicalTrials.gov registry record · NA

WORTH Paths Intervention

A NA study of Substance Use Disorder (SUD) and Sexual Risk Behavior, sponsored by Fairleigh Dickinson University.

Recruiting
Registry status
NA
Development phase
50
Enrollment target
1
Study location

NCT06889831: Recruiting NA study of Substance Use Disorder (SUD) and Sexual Risk Behavior, sponsored by Fairleigh Dickinson University.

NCT06889831 is a NA study of Substance Use Disorder (SUD) and Sexual Risk Behavior that is actively recruiting participants, run by Fairleigh Dickinson University. The registered enrollment target is 50 participants, below the 246-participant average among 15 other Substance Use Disorder (SUD) trials with a reported enrollment target (80% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06889831, a NA study of Substance Use Disorder (SUD) and Sexual Risk Behavior, is actively recruiting participants, sponsored by Fairleigh Dickinson University.

RECRUITING
Registry status
NA
Development phase
50 participants
Enrollment target
1
Study location

Study Summary

Women in the criminal legal system are more likely to experience substance use disorders and unintended pregnancy than women in the general public. However, they often face barriers to accessing substance use treatment and sexual and reproductive health services. This study tests the feasibility and acceptability of Women on the Road to Health (WORTH) Promoting Access to Treatment, Health, and Support (Paths), a digital intervention adapted from the evidence-based CDC Best Practice HIV prevention intervention, Women on the Road to Health (WORTH), originally developed at Columbia University School of Social Work. WORTH Paths is designed to help reproductive-aged women in the criminal legal system with substance use disorders and unmet need for contraception reduce drug use and improve contraceptive use. Participants (N=50) will be randomly assigned to one of two groups: WORTH Paths Intervention Group - Participants will attend three virtual group sessions with facilitated videoconference sessions and self-paced digital activities focused on reducing drug use and increasing contraceptive use. They will also receive guidance on how to access and navigate health services. Control Group - Participants will receive a virtual general wellness program that includes education on substance use and sexual and reproductive health but does not include skills-based training related to these topics. The focus will be on general wellness and stress reduction. Both groups will receive resources for substance use treatment and sexual and reproductive health services. Researchers will track changes in drug use and contraceptive use over three months. Participants will complete surveys and provide urine samples to confirm changes in drug use. Primary aims: Feasibility: Measured by session attendance, treatment completion, dropouts, and reasons for termination. Acceptability: Measured by participant ease of use, helpfulness, and satisfaction. Primary behavioral outcomes: Self

Primary Outcome

Percentage of participants who complete all three intervention sessions, which occur once per week over a three-week period. Completion is defined as attending all sessions and engaging in digital interactive components.

Interventions

  • BEHAVIORAL WORTH Paths Digital Intervention
  • BEHAVIORAL WORTH Paths Wellness Group

Study Locations (1)

New Jersey

  • Fairleigh Dickinson University - Teaneck

Trial Details

FieldValue
Enrollment Target 50 participants
Start Date 2025-08-12
Est. Completion 2026-04-01
Phase NA
Fairleigh Dickinson University

1 total trials

What NCT06889831 shows while recruiting

NCT06889831 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 50 participants, a relatively small participant target, below the 246-participant average among 15 other Substance Use Disorder (SUD) trials with a reported enrollment target (80% lower).

The record links to 3 conditions, with Substance Use Disorder (SUD) appearing as the primary indexed condition, and to 2 interventions - of which WORTH Paths Digital Intervention is the first listed.

NCT06889831 reports a single indexed study location in New Jersey.

Frequently Asked Questions

What is clinical trial NCT06889831 about?

NCT06889831 is a clinical study titled "WORTH Paths Intervention". Women in the criminal legal system are more likely to experience substance use disorders and unintended pregnancy than women in the general public. However, they often face barriers to accessing substance use treatment and sexual and reproductive health services. This study tests the feasibility an...

What is the current status of trial NCT06889831?

This trial is currently recruiting. It is a NA study. The enrollment target is 50 participants. The study started on 2025-08-12. Estimated completion is 2026-04-01.

What conditions does trial NCT06889831 study?

This clinical trial studies the following conditions: Substance Use Disorder (SUD), Sexual Risk Behavior, Sexual and Reproductive Health.

What interventions are being tested in trial NCT06889831?

The interventions under investigation include: WORTH Paths Digital Intervention (BEHAVIORAL), WORTH Paths Wellness Group (BEHAVIORAL).

Who is sponsoring clinical trial NCT06889831?

This trial is sponsored by Fairleigh Dickinson University, which has 1 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06889831 being conducted?

This trial has 1 study location across New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Substance Use Disorder (SUD)

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT06889831's enrollment target sits among peer trials

50 10th of 15 higher than 4 of 15 other Substance Use Disorder (SUD) trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Substance Use Disorder (SUD) trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00200889 · 50 participants · Early Phase 1

    Mapping Auricular Vagus Nerve Circuitry

  • NCT00409435 · 50 participants · Phase 2

    A Study of Pyridostigmine in Postural Tachycardia Syndrome

  • NCT01202305 · 50 participants

    The Use of Lymph Node Biopsies to Support HIV Pathogenesis Studies

  • NCT01225913 · 50 participants · Phase 4

    Mechanism(s) of Airflow Limitation During Exacerbation of Asthma

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT06889831, the US trial registry maintained by the National Library of Medicine. NCT06889831 (small enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.